The Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO; ex-V3SWG) Working Group has developed a standardized template to describe the key considerations for the benefit-risk assessment of the Auro Vaccines LLC protein vaccine to prevent disease from Nipah and Hendra virus infection. This template is now undergoing peer review. Brighton Collaboration encourages members to peer review this template using the google form below before June 25th, 2021.
“A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 p...
